Groundbreaking Study on Lacunar Ischemic Stroke
July 5, 11:00 PM
Contrary to long-held assumptions, a recent study in the journal Circulation reveals that lacunar ischemic strokes stem from abnormal widening and elongation of tiny brain blood vessels, not fatty plaque buildup. By analyzing data from 229 individuals who had experienced either a lacunar or mild non-lacunar stroke, researchers found no correlation between arterial narrowing and lacunar lesions. Patients with dilated microvessels faced more than a fourfold higher likelihood of developing a lacunar stroke.
Research Methods and Key Findings
Participants underwent MRI scans immediately after their stroke and again one year later. The results showed that one in four patients had silent strokes. These insights have paved the way for the LACI-3 clinical trial, which is testing drugs designed to protect small blood vessels—specifically cilostazol and isosorbide mononitrate. Funded by UK medical foundations, this project also involves researchers from China and Mexico.
'Recognizing the microvascular origins of lacunar stroke is essential for developing effective treatments,' said Professor Joanna Wardlaw.
Conventional medications like aspirin and antiplatelet drugs have shown limited effectiveness against lacunar stroke, highlighting the urgent need for fresh prevention and treatment strategies.
This research opens new avenues for understanding how lacunar strokes develop, potentially reshaping therapeutic approaches. Given the complexity of this condition, the findings could drive further scientific innovation and improve clinical care, ultimately reducing the risk of recurrent strokes. The LACI-3 trial holds promise as a major step forward, offering new hope for patients suffering from lacunar ischemic stroke.